#Nuvectis Pharma Advancements in NSCLC Treatment Amidst Financial Challenges

Biomarker-Specific Survival and Cost for Advanced NSCLC

#Nuvectis Pharma Advancements in NSCLC Treatment Amidst Financial Challenges

In a significant stride towards improving the treatment landscape for non-small cell lung cancer (NSCLC), Nuvectis Pharma has announced the publication of a research study conducted at the Lerner Research Institute, part of the Cleveland Clinic at Case Western Reserve University. The study highlights the potential of the combination of NXP900 and epidermal growth factor receptor (EGFR) inhibitors to enhance the efficacy of existing EGFR inhibito…

Identification of C4BPA as a genetically informed drug target in NSCLC: An integrative single-cell and multi-omics study based on the druggable genes

Background Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide. Despite advancements in treatment, drug resistance and limited therapeutic efficacy persist, underscoring the urgent need for novel and mechanistically informed therapeutic str...

Taletrectinib: A New Advance in ROS1-Mutant NSCLC

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.